ACTRN12618001559202尚未招募不适用
Auto-escalation of deteriorating patients using real-time vital signs monitoring in acute care settings
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients on General Medicine ward of North Shore Hospital (male and female).
排除标准
- •Exclusion of refusal of inform consent; Hodkinson AMT 7/10 or less (Hodkinson H. M., 1972), patients deemed unsuitable by medical or nursing staff, terminally ill patients and patients on any other monitoring device.
- •Reference: Hodkinson H. M. (1972). EVALUATION OF A MENTAL TEST SCORE FOR ASSESSMENT OF MENTAL IMPAIRMENT IN THE ELDERLY. Age and Ageing, 1, 233-238.
研究者
相似试验
已完成
不适用
Control of patients who present themselves in the emergency room by means of a structured initial medical assessment in Germany” (SmED): Evaluation of SmED-Kontakt +no specific diagnoses, emergency room patientsDRKS00026988Zentralinstitut für die Kassenärztliche Versorgung in Deutschland (Zi)2,181
尚未招募
不适用
The effects of Posture and Continuous Positive Airway Pressure (CPAP) on lung function in patients recovering from an acute exacerbation of heart failureCardiovascular - Other cardiovascular diseasesRespiratory - Other respiratory disorders / diseasesHeart FailureACTRN12610000556044Professor Matthew Naughton100
已完成
不适用
Immediate in-hospital reactivation of patients with an exacerbation of Chronic Obstructive Pulmonary Disease (COPD): Pulmofit-MSTChronic Obstructive Pulmonary Disease (COPD)RespiratoryChronic obstructive pulmonary disease (COPD)ISRCTN99715969Dutch Asthma Foundation (The Netherlands)80
进行中（未招募）
不适用
A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCOPatients with any malignancy who have previously been evaluated in a SU011248 protocolEUCTR2005-005335-94-DEPfizer Pharma GmbH300
进行中（未招募）
1 期
A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCOPatients with any malignancy who have previously been evaluated in a SU001248 protocolEUCTR2005-005335-94-NLPfizer BV